These incorporate high-dose cytarabine during induction and consolidations, include nucleoside analogs into the regimens, may incorporate lower-dose GO as part of induction-consolidation in CBF and intermediate-karyotype AML, may add other targeted therapies, particularly FLT3 inhibitors (e.g., gilteritinib, midostaurin, sorafenib) in FLT3-mutated AML, and may add venetoclax to regimens in non FLT3- mutated AML (discussed later). Here, FLT3 is linked to acute myeloid leukemia.